LENZ Therapeutics

LENZ · NASDAQ

$3.19−$0.11 (−3.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.30

About LENZ

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 152 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Employees: 152
Headquarters: Solana Beach, California
Listed: Jun 25, 2021
Sector: Health Care
Industry: Pharmaceuticals
Website: lenz-tx.com

Leadership

LENZ Therapeutics executives
Name	Title	Since	Age
Jeff George	—	—	51
Evert Schimmelpennink	—	2024	53
Daniel Chevallard	—	—	44
Marc Odrich	—	—	66
Shawn Olsson	—	—	42
Kimberlee Drapkin	—	2023	57
Frederic Guerard	—	—	53
James Mccollum	—	—	70
Zachary Scheiner	—	—	48
Shelley Thunen	—	—	72

Similar companies

Companies in the same industry as LENZ Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.